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Abstract
Introduction: Trigeminal neuralgia (TN) is characterized by touch-evoked unilateral brief shock-like paroxysmal pain in
one or more divisions of the trigeminal nerve. In addition to the paroxysmal pain, some patients also have continuous
pain. TN is divided into classical TN (CTN) and secondary TN (STN).
Etiology and pathophysiology: Demyelination of primary sensory trigeminal afferents in the root entry zone is the
predominant pathophysiological mechanism. Most likely, demyelination paves the way for generation of ectopic impulses
and ephaptic crosstalk. In a significant proportion of the patients, the demyelination is caused by a neurovascular conflict
with morphological changes such as compression of the trigeminal root. However, there are also other unknown
etiological factors, as only half of the CTN patients have morphological changes. STN is caused by multiple sclerosis
or a space-occupying lesion affecting the trigeminal nerve.
Differential diagnosis and treatment: Important differential diagnoses include trigeminal autonomic cephalalgias,
posttraumatic or postherpetic pain and other facial pains. First line treatment is prophylactic medication with sodium
channel blockers, and second line treatment is neurosurgical intervention.
Future perspectives: Future studies should focus on genetics, unexplored etiological factors, sensory function, the
neurosurgical outcome and complications, combination and neuromodulation treatment as well as development of new
drugs with better tolerability.
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Definition
According to the beta version of the 3rd edition of the
International Classification of Headache Disorders
(ICHD-3 Beta) (1) (Table 1), trigeminal neuralgia
(TN) is defined by recurrent unilateral brief electric
shock-like pain that is abrupt in onset and termination.
The pain is restricted to one or more of the trigeminal
divisions and is triggered by innocuous sensory stimuli.
TN is divided into either classical TN (CTN) or second-
ary TN (STN) caused by multiple sclerosis or a space-
occupying lesion such as a tumor, cerebral aneurism or
a megadolicho basilar artery.
Recently the International Association for the Study
of Pain (IASP) has produced an independent classifica-
tion, definition, and diagnostic process of trigeminal
neuralgia (TN) (2). It is a main aim of both societies
to find a bilaterally agreed compromise, for the sake of
researchers and clinicians and ultimately of patients.
Table 1 outlines the two classifications.
Symptomatology
In early descriptions of TN, the disorder was called tic
douloureux (3), addressing the characteristic wince that
TN patients may exhibit at a pain paroxysm; TN pain is
not only extremely painful, it is also characteristic that the
pain is sudden and unexpected, and short-lasting, hence
the term pain paroxysm. The pain quality is stabbing,
electrical shock-like, or shooting. Although one single
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pain paroxysmmay only last a fraction of a second, these
paroxysms may recur, after a refractory period, many
times a day, and they may come in a series of attacks
with many paroxysms close together.
Approximately half of the TN patients also have
concomitant continuous pain: an aching or dull or
burning background pain of lower intensity in the
same area as the paroxysmal pain (4–6). The
continuous pain is usually present during the same per-
iods as the paroxysmal pain. This background pain is
most common in women (4,7,8).
Refractory period and trigger factors
Many patients experience a refractory period after a par-
oxysmal attackwhere new attacks cannot be elicited. The
Table 1. Diagnostic criteria of trigeminal neuralgia according to the beta-version of the 3rd edition of the International Classification of
Headache Disorders (ICHD3-beta) and to the International Association for the Study of Pain (IASP) (shortened and adapted versions).
ICHD3-beta
Definition Outlined in main manuscript
Criteria* A. At least three attacks of unilateral facial pain fulfilling criteria B and C
B. Occurring in one or more divisions of the trigeminal nerve, with no radiation beyond the trigeminal
distribution
C. Pain has at least three of the following four characteristics:
1. recurring in paroxysmal attacks lasting from a fraction of a second to 2 minutes
2. severe intensity
3. electric shock-like, shooting, stabbing or sharp in quality
4. precipitated by innocuous stimuli to the affected side of the face
D. No clinically evident neurological deficit
E. Not better accounted for by another ICHD-3 diagnosis
Subclassification Classical TN
- TN with purely paroxysmal pain
- TN with concomitant persistent pain
Symptomatic TN**
- TN associated to multiple sclerosis (MS): MS has been diagnosed and MRI demonstrates MS plaque affecting the
trigeminal nerve root or electrophysiological studies indicate impairment of the affected nerve(s). Pain is not
necessarily unilateral***
- TN associated to space-occupying lesion: contact between a space-occupying lesion and the affected trigeminal
nerve has been demonstrated by imaging and pain has developed after contact occurred between the lesion
and the trigeminal nerve, or led to its discovery
Comments *In the forthcoming final ICHD3 criteria C1, 2, 3 and 4 of ICHD3-beta will most likely be converted into
individual monothetic criteria and criterion D of ICHD3-beta will most likely be deleted
**In ICHD3-beta symptomatic TN is termed painful trigeminal neuropathy but this will most likely be changed
back to symptomatic TN in the forthcoming final ICHD3
*** In the forthcoming final ICHD3 the criteria demanding an MRI-verified plaque affecting the trigeminal root or
electrophysiological cerification will most likely be removed
IASP
Defintion Orofacial pain restricted to one or more divisions of the trigeminal nerve. With the exception of TN caused by
multiple sclerosis, the pain affects one side of the face. It is abrupt in onset and typically lasts only a few
seconds (2 minutes at maximum). Patients may report their pain as arising spontaneously but these pain
paroxysms can always be triggered by innocuous mechanical stimuli or movements. If patients experience
additional continuous pain in the same distribution and same period as the paroxysmal pain it is considered to
be TN with concomitant continuous pain and this phenotype may be present in each of the three subclassi-
fication categories
Criteria A. Orofacial pain distributed within the trigeminal facial or intraoral territory
B. Paroxysmal character of pain
C. Pain triggered by typical maneuvers
Subclassification - Idiopathic TN: no apparent cause
- Classical TN: caused by vascular compression of the trigeminal nerve root resulting in morphological changes of
the root
- Secondary TN: caused by major neurological disease, e.g., a tumour of the cerebellopontine angle or multiple
sclerosis
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pathophysiological mechanism of this phenomenon is
unknown. It has beenproposed that it is caused byhyper-
polarisation of the sensory neuron (9). In early studies by
Kugelberg and Lindblom, the presence and duration of
the refractory period in TN was a function of the inten-
sity and duration of the preceding attack (10).
It is highly characteristic that pain is triggered by
innocuous sensory stimuli to the affected side of the
face. Sensory stimuli may be extraoral and intraoral.
The most frequent trigger factors involve normal daily
activities such as light touch, talking, chewing, brushing
teeth and cold wind against the face (11,12). It has been
suggested that apparently spontaneous pain paroxysms
may in fact be elicited by very subtle sensory stimuli or
movements.
Localisation
TN most frequently affects the 2nd and/or 3rd trigeminal
division and the right side is slightly, but significantly,
more often affected than the left side (11). Bilateral TN
is very rare in classical TN, and should raise suspicion
of secondary TN.
Natural history
There are very few studies examining the natural his-
tory of TN. It has been proposed that pain may worsen
with time and that TN in its chronic state is charac-
terised by longer lasting, medically refractory pain, sen-
sory disturbances and progressive neuroanatomical
changes of the trigeminal root (8). Several studies
have now challenged this notion; Di Stefano et al.
found that in the majority of TN patients the pain
does not increase in frequency or duration, nor did it
become refractory to medication, and the dosage
needed to relieve pain did not increase with time (13).
Maarbjerg et al. found that concomitant persistent pain
and neuroanatomical morphological changes were not
related to age or to duration of disease (4,7).
A feature that is also very characteristic to the course of
TN is unpredictable periods of complete remission that
may last months or even years. This unusual
phenomenon in neuropathic pain is most likely attributed
to a reduction in excitability and partial remyelination (9).
Autonomic symptoms in facial pain
Traditionally, autonomic symptoms such as tearing
and rhinorrhea have not been associated with TN.
However, it is now known that a large proportion of
TN patients have autonomic symptoms from time to
time (11,12,14). Keeping in mind that the trigeminovas-
cular reflex can be elicited by intense facial pain in gen-
eral (15), it is not surprising that there can be sporadic
autonomic symptoms in TN. The challenge is related to
differential diagnosis; short-lasting triggered stabbing
pain with pronounced and consistent autonomic
symptoms is characteristic of short-lasting unilateral
neuralgiform headache attacks with conjunctival
injection and tearing (SUNCT), and short-lasting uni-
lateral neuralgiform headache attacks with autonomic
symptoms (SUNA) (16).
Epidemiology
TN is frequently both misdiagnosed and underdiag-
nosed. The incidence of TN is variably reported between
studies, with a range from 4.3 to 27 new cases per
100,000 people per year (17–19). The incidence is
higher among women, and increases with age (17).
The lifetime prevalence was estimated to be 0.16–0.3%
in population-based studies (18,20). The average age of
onset is 53 years in classical TN and 43 years in second-
ary TN, but the age of onset can range from early to old
age (11,21). In tertiary care-based studies, STN
accounted for 14–20% of TN patients (11,22).
Etiology and pathophysiology
As early as 1934, Dandy proposed that in at least 30%
of TN patients the pain was caused by a blood vessel
compressing the trigeminal nerve (23). Today, it is gen-
erally agreed that the most common cause of classical
TN is compression or other morphological changes of
the trigeminal nerve by a blood vessel, usually an
artery, in the cerebellopontine cistern. This is termed
a neurovascular conflict with compression.
Anatomical studies documented that the transition
from Schwann cell myelination to oligodendroglia mye-
lination in many specimens tapers gradually along the
proximal 25% of the nerve (24). Possibly, this ‘‘transi-
tion zone’’ represents a particularly vulnerable area to,
for example, pressure from a blood vessel.
Emerging evidence indicates that a neurovascular
conflict involving morphological changes of the trigem-
inal nerve such as distortion, dislocation, distension,
indentation, flattening or atrophy is highly associated
with classical TN and is present in about half of the TN
patients (Figure 1) (25–27). Conversely, it is debated
whether a neurovascular conflict without morpho-
logical changes of the trigeminal nerve, a ‘‘simple
contact’’, where the two structures are merely touching,
is important to TN etiology. On the one hand, a simple
neurovascular contact was also, however much less,
associated to TN (25,26) and microvascular decompres-
sion was also reported to be effective in TN patients
with a simple neurovascular contact (28). On the
other hand a simple contact was a very prevalent find-
ing in cadavers without a history of TN, in healthy
650 Cephalalgia 37(7)
subjects and on the asymptomatic side in TN patients
(25,29–31). In patients with persistent idiopathic facial
pain, an important differential diagnosis to TN, the
prevalence of neurovascular conflict is similar to that
found in asymptomatic nerves (32). Thus, a neurovas-
cular conflict should be considered a normal neuroana-
tomic variant in patients with facial pain not fulfilling
the TN diagnostic criteria. A hypothetical exception to
this rule is that some TN patients only have persistent
pain at onset, previously termed ‘‘pretrigeminal neural-
gia’’, and thereafter develop the classical paroxysmal
pain (4,33). Such patients do not initially fulfill the
TN diagnostic criteria.
Although it is not yet clear which other etiological
factors might contribute to or cause TN, there are
numerous neurophysiological, neuroimaging and
histological studies pointing to focal demyelination of
primary trigeminal afferents near the entry of the
trigeminal root into the pons as the underlying patho-
physiological mechanism in TN (34–36). The
consequences of the demyelination are not fully clari-
fied, but it has been hypothesised that the focally
demyelinated primary afferents become hyperexcitable
when demyelination reaches such a level that ions can
move in and out of the axon, also away from the
Ranvier node zones, at which point the axons do not
have enough energy to promptly re-establish the resting
potential. Hence the axons tend towards a depolarisa-
tion level, which makes them hyperexcitable. Ectopic
impulses, which are generated either spontaneously
along the sensory afferent or because of a local direct
mechanical stimulus such as arterial pulsation, are
probably also involved in the hyperexcitability.
Moreover, supported by evidence in animal models of
focal demyelination of the trigeminal root, ephaptic
transmission, i.e. cross-talk from close, healthy nerve
fibres, and the generation of high-frequency discharges
are also suggested to contribute to the hyperexcitable
nervous state in TN (9,37,38).
Finally, there is some evidence suggesting that
the hyperactivity of primary afferents secondarily
induces central sensitisation of wide-dynamic-range
neurons in the spinal trigeminal nucleus or even
more central changes (36,39). Future investigations
are needed.
In secondary TN, the pathophysiological mechanism
is most likely the same as in classical TN but the eti-
ology is dependent on the specific structural lesion,
most frequently an MS plaque affecting the trigeminal
root or a space-occupying lesion in the cerebellopontine
cistern such as epidermoid tumours, meningiomas,
neurinomas, arteriovenous malformations or aneur-
ysms (Figure 2) (40,41).
Diagnostic considerations
The diagnosis of TN is primarily based on patient his-
tory, as there are no definitive laboratory or diagnostic
tests. When obtaining patient history, special attention
should be paid to the potential pitfalls leading to mis-
diagnosis such as a symptomatic cause of pain, odon-
togenic pain and associated autonomic symptoms
(Table 2). When obtaining patient history, one should
pay special attention to the onset of pain; if the pain
was preceded by or coincided with a herpes zoster rash
in the ipsilateral trigeminal distribution, painful trigem-
inal neuropathy attributed to acute herpes zoster
Figure 1. MRI in a patient with left-sided classical trigeminal
neuralgia. Balanced fast field echo sequence of the fossa poster-
ior, axial plane, at the level of the pons. The left trigeminal nerve
(right-sided arrowhead) is displaced by an arterial loop (arrows)
from the anterior inferior cerebellar artery.
Figure 2. MRI in a patient with left-sided symptomatic tri-
geminal neuralgia. Balanced fast field echo sequence of the fossa
posterior, axial plane at the level of the pons. The peripheral part
of the left trigeminal nerve is displaced by a meningioma (both
structures encircled).
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should be considered (42). In pain preceded by a rele-
vant trauma to the ipsilateral side of the face, such as
invasive dental procedures or fractures, painful post-
traumatic trigeminal neuropathy (PPTN) is more
likely the correct diagnosis. Studies have shown that
pain in PPTN may be comparable to TN pain with
short, intense triggered pain, but in PPTN there are
usually clear cut sensory abnormalities, including
both loss and gain of function, corresponding to the
damaged peripheral nerve (29). Also important when
obtaining the patient history is the location of pain;
pain originating distinctly or diffusively from the teeth
should be evaluated by a dentist because, for example, a
cracked tooth may present with TN-like pain evoked by
chewing hard foods. In bilateral constant pain located
in the temporomandibular area, tension-type headache,
temporomandibular joint disorder and persistent idio-
pathic facial pain should be considered. If the short-
lasting, intense stabbing pain is isolated to the scalp
or occipital area, diagnoses such as occipital neuralgia,
primary stabbing headache and paroxysmal hemicrania
should be considered. Glossopharyngal neuralgia is
located to the back of the tongue, the soft palate and
the pharynx, and nervus intermedius neuralgia is
located deep in the ear. Finally, associated symptoms
are important; if each pain attack is accompanied by
autonomic symptoms such as conjunctival injection,
miosis or lacrimation, SUNA, SUNCT or paroxysmal
hemicrania are important differential diagnoses.
Treatment
Figure 3 outlines a proposed work-up and treatment
algorithm in TN. As a part of the early work-up, we
suggest including an MRI of the brain and brainstem,
ECG and laboratory testing. As symptomatic and clas-
sical TN cannot be confidently separated based on his-
tory and examination (43), an MRI is important early
on to exclude a symptomatic cause of pain that could
warrant specific treatments, such as tumors or multiple
sclerosis. Laboratory testing is performed to ensure
normal renal and liver function and normal sodium
level prior to prescription of medication. ECG is war-
ranted because carbamazepine and oxcarbazepine are
contraindicated in patients with atrioventricular block.
First line treatment is sodium channel blockers, either
carbamazepine or oxcarbazepine. They have the same
mechanism of action, namely the blockade of voltage-
gated sodium channels in a frequency-dependent man-
ner. Treatment recommendations are generally the
same in classical and secondary TN (43). Generally,
sodium channel blockers are effective in most TN
patients and the number needed to treat for carbamaze-
pine is 1.7 (44–46). However, side effects including som-
nolence, drowsiness, dizziness, rash, and tremor are
frequent and the number needed to harm for carba-
mazepine is 24 for severe side effects and 3.4 for
minor side effects (43). Oxcarbazepine may be preferred
because of a minor risk of drug interactions and its
Table 2. Differential diagnosis in trigeminal neuralgia.
The symptomatology of trigeminal neuralgia is typically very characteristic, with patients reporting intense stabbing touch-evoked
unilateral facial pain in the cheek, the area of the nostrils, teeth or jaw. Primary and secondary, i.e. pain secondary to multiple
sclerosis or space-occupying lesion, TN may be indistinguishable based on pain characteristics. Meanwhile, in patients with sec-
ondary TN, neurological deficits, extra-trigeminal symptoms, bilateral pain and young onset are more frequent.
Primary and secondary headache and facial pain differential diagnosis includes:
 Glossopharyngeal neuralgia causes evoked stabbing pain located to the back of the tongue, the pharynx or deep in the ear.
Trigger factors are somewhat different from TN and include swallowing, coughing, sneezing
 Painful posttraumatic trigeminal neuropathy can cause stabbing and touch-evoked pain similar to TN, but pain is by
definition preceded by trauma and there are usually clear-cut neurological abnormalities of both gain and loss of function cor-
responding to the affected peripheral nerve
 Persistent idiopathic facial pain causes touch-evoked or spontaneous dull or aching constant pain
 Painful trigeminal neuropathy attributed to acute herpes zoster causes burning and stabbing pain preceded by a herpetic
rash in the trigeminal distribution. Tingling sensations and neurological abnormalities with both gain and loss of function are
frequent
 Short-lasting unilateral neuralgiform headache attacks with autonomic symptoms (SUNA), short-lasting unilat-
eral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or paroxysmal hemicrania
cause touch-evoked and spontaneous stabbing orbital, supraorbital or temporal pain accompanied by ipsilateral autonomic symp-
toms. Unlike TN, pain may change side
 Cluster headache causes orbital, supraorbital or temporal pain accompanied by ipsilateral autonomic symptoms and restless-
ness. Duration is from 15–180 minutes. Unlike TN, pain may change side
 Primary stabbing headache causes stabbing spontaneous pain in the scalp and is not accompanied by autonomic symptoms
Odontogenic differential diagnosis:
 Cracked tooth can cause evoked shooting pain when chewing hard foods
 Caries or pulpitis can cause evoked pain at intake of sweet, cold or hot foods. The pain can last from ten minutes up to hours
*Autonomic symptoms are conjunctival injection, lacrimation, rhinorrhea, nasal congestion, sweating, miosis, ptosis and eyelid edema.
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better tolerability in comparison with carbamazepine.
Carbamazepine was reported to have a higher percent-
age of discontinuation due to all kinds of side effects,
except for sodium depletion, for which discontinuation
only occurred with oxcarbazepine (13).
Very often high dosages are necessary for sufficient
pain relief, so many patients suffer from disabling side-
effects. Treatment failure is typically not due to drug
inefficacy, but rather due to undesired side effects that
causes interruption of treatment or dosage reduction to
an insufficient level. In one study, worsening of pain
with time and development of late resistance only
occurred in a very small minority of patients (13).
According to the international guidelines it is
advised that ‘‘if any of these sodium-channel blockers
is ineffective, referral for a surgical consultation would
be a reasonable next step’’ (43). Surgery should also be
considered when drugs, although effective, cannot
reach the therapeutic dosage due to adverse events.
From a clinical perspective, it may also be reasonable
to try out both carbamazepine and oxcarbazepine
sequentially. Furthermore, many TN patients benefit
from add-on treatment combining carbamazepine or
oxcarbazepine with lamotrigine, baclofen, pregabalin
or gabapentin. Combination treatment should be con-
sidered when carbamazepine or oxcarbazepine cannot
reach full dosage because of side effects. Each of the
above-mentioned drugs may also have efficacy as
monotherapeutic agents, although the available evi-
dence is very weak (43). At severe exacerbations, in-
hospital treatment may be necessary for titration of
antiepileptic drugs and rehydration. In many centres,
severe exacerbation is treated with intravenous loading
of fosphenytoin, but there is a lack of scientific evidence
for this treatment.
In medically refractory patients, with a neurovascu-
lar conflict, microvascular decompression (MVD) is the
first choice treatment (43). This procedure implies
Work up
History: onset (trauma or herpes?), quality, intensity, 
duration and localization of pain, autonomic ipsilateral
symptoms, other neurological or medical complaints
Exam: general clinical and neurological examination
focusing on trigeminal sensory function and signs of 
multiple sclerosis or cerebellopontine tumor
Paraclinical work up: ECG, blood tests (electrolytes, 
liver and kidney function) and MRI of the brain and 
brainstem are mandatory
Diagnosis
Differential diagnosis: is there another diagnosis that
is more likely? Has the patient consulted a dentist?
Diagnostic criteria: are the diagnostic criteria
fulfilled?* Is it primary or secondary trigeminal
neuralgia? 
Information: provide thorough patient information on 
medical and surgical treatment options and their
expected rate of success, side effects and 
complications
Medical treatment
Titrate slowly and taper off even slower. Secondary TN 
is treated according to the same principles as listed
below
1. Sodium channel blockers: carbamazepine and 
       oxcarbazepine
2. Add on or monotherapeutic treatment
      lamotrigine, baclofen, pregabalin or gabapentin
: 
Challenges: cognitive side effects, hyponatriemia, co-
morbid cardiac, hepatic or renal disease, women in 
fertile age using oral contraceptives or planning on 
pregnancy
Second line surgical treatment
First choice: Microvascular decompression if 
neurovascular contact has been demonstrated
Second choice: stereotactic radiosurgery, glycerol 
blockade, balloon compression, radiofrequency
thermocoagulation
Secondary TN: in multiple sclerosis follow the
treatment principles listed above including
microvascular decompression if there is a 
neurovascular contact. At a space-occupying lesion it 
depends on the specific lesion
Follow up: ask about complications. Some patients 
will still need medication after surgery – establish a 
close co-operation between the neurologist, 
neuroradiologist and neurosurgeon
Figure 3. Work up and treatment algorithm in trigeminal neuralgia (TN) – presented in short. Diagnostic criteria of TN are outlined
in Table 1.
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craniotomy and posterior fossa exploration for identi-
fication of the affected trigeminal nerve and the
conflicting blood vessel(s). Microvascular decompres-
sion provides the longest duration of pain freedom in
comparison with other surgical techniques, as it report-
edly provides significant pain relief in 73% of patients
after five years. Minor complications such as new
aching or burning pain, sensory loss and other mild
or transient cranial nerve dysfunction occur in 2–7%.
Major complications such as major cranial nerve dys-
function (2%), stroke (0.3%) and death (0.2%) are
rare, yet it is important to inform patients of the poten-
tial risks (47). In most previous studies, the surgical
complications were not reported by independent asses-
sors and therefore the complication rates may be
higher. The conventional opinion that multiple sclerosis
is a contraindication to microvascular decompression
has recently been refuted by a study showing that in
some multiple sclerosis patients with TN, a neurovas-
cular conflict may act as a concurring mechanism in
producing focal demyelination of the primary afferents
at the root entry zone (48).
Second choice neurosurgical treatments are lesioning
peripheral procedures targeting the trigeminal ganglion
chemically by glycerol blockade, mechanically by bal-
loon compression, or thermically by radiofrequency
thermocoagulation. In stereotactic radiosurgery
(‘‘gamma knife’’) the target is the trigeminal root,
which is lesioned by convergent beams of radiation.
The procedures are efficacious in approximately 50%
of patients after five years, and minor complications
such as sensory loss (12–50%), masticatory problems
(balloon compression (up to 50%)) and new burning or
aching pain (12%) are relatively prevalent (43).
The above-mentioned treatment recommendations
are mainly based on expert opinion. There is a lack of
robust scientific evidence for effect and side-effects of
both medical and surgical treatment of TN.
Expert opinion: Open questions and
burning desires
There are a number of open questions in TN that
remain to be answered. Questions relate both to
pathophysiology, etiology, genetics, natural history,
treatment and classification.
Pathophysiology and etiology
To date, only very few animal models of TN have
sought to mimic demyelination of the prepontine seg-
ment of the trigeminal nerve (38), other models have
been based on more peripheral trigeminal nerve
trauma. Proper animal models of TN could help
elucidate the pathophysiological mechanisms behind
TN. As previously discussed, neurovascular conflict
with morphological changes of the trigeminal root
was identified as a major etiological factor in TN,
confirming the vast amount of neurosurgical studies
supporting that microvascular decompression is effect-
ive in TN. However, firstly, only half of TN patients
have morphological changes of the ipsilateral trigem-
inal nerve, and 12% of patients do not even have a
neurovascular conflict (25,26), and secondly, the recur-
rence rate after microvascular decompression is about
2% annually, and in approximately 30% of patients the
procedure does not provide long-term pain relief (47).
This indicates that either microvascular decompression
was not able to reverse the hyperexcitable state of the
trigeminal root induced by a neurovascular conflict, or
that the de- and dysmyelination of the trigeminal root
can also be caused or maintained by other unknown
etiological factors.
There are no confirmed risk factors in TN as studies
(11,12) have failed to reproduce hypertension as a risk
factor, which was reported by Katusic (17). There is a
slight preponderance of women with TN; women gen-
erally have a younger age of onset and less frequently
have morphological changes of the ipsilateral trigem-
inal root. Therefore, factors relating to the female sex,
such as differences in sex hormone levels, may be risk
factors in TN, but this has yet to be explored. Another
virtually unexplored risk factor may be gain-of-func-
tion mutations of voltage gated sodium channels.
Mutations were identified in other pain conditions
somewhat resembling TN, such as paroxysmal extreme
pain disorder, erythromelalgia, and small fiber neur-
opathy (49–51). A recent study identified a single
NaV1.6 de novo missense mutation causing increased
trigeminal excitability in a CTN patient (52).
Classification
The terminology of TN type 1 (more than 50% parox-
ysmal pain) and 2 (more than 50% constant pain) (53)
is widely used, especially in neurosurgical literature. A
possible drawback to this proposed classification
system is that patients with idiopathic constant facial
pain and no paroxysmal pain, could be classified as TN
type 2, where other classification systems would desig-
nate the diagnosis of persistent idiopathic facial pain
(formerly atypical facial pain) to such patients.
Recently, it was suggested that classical TN should
be divided into an idiopathic form and a classical form
where there are morphological changes of the trigem-
inal root (2). If in fact the etiology is multifactorial in
some patients, involving both neurovascular conflict
and other factors that may lead to demyelination or
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hyperexcitability, such a classification scheme is chal-
lenging and there is a need for studies exploring
whether this proposed division is meaningful in a clin-
ical and scientific context.
Maarbjerg et al. reported evidence of sensory
abnormalities in TN, in particular hypesthesia, at clin-
ical examination (11). Younis et al. demonstrated sen-
sory abnormalities by quantitative sensory testing
blinded to symptomatic side even in patients with no
clinically evident sensory abnormalities (54). Similar
results were also reported by others (21,47,55).
Findings may be explained by central pain-induced
functional changes (56).
Clinical practice
There is a need for prospective studies into TN nat-
ural history to clarify whether TN progress with
time, stays the same, or improves with old age.
There is a huge lack of well-designed studies investi-
gating the efficacy and side-effects of prophylactic
medications for TN. Further studies should also
look into the efficacy of intravenous fosphenytoin
loading, combination treatments, botolinum toxin
and neurostimulation. It is debated when and
which patients should be referred to surgery. There
is a lack of well-designed prospective neurosurgical
trials using independent evaluators of diagnosis and
outcome (57).
Expert opinion: Where
the field needs to go
Future studies should focus on co-operation between
neurologists, neurosurgeons and neuroradiologists as
well as co-operation between multiple centres to
ensure a high quality, continuing discussion among
specialised centres and large patient volumes in the
much needed medical trials, longitudinal surgical and
medical follow up and interventional studies. New
sodium channel blockers are in the pipeline, but neuro-
stimulation and botolinum toxin may also represent
promising treatments in medically refractory patients
(58–60).
Article highlights
. Trigeminal neuralgia (TN) is characterised by unilateral, intense, touch-evoked, stabbing paroxysmal pain.
It typically affects the second and third trigeminal branch.
. Trigeminal neuralgia can be either idiopathic or secondary to multiple sclerosis or a space-occupying lesion.
. A neurovascular conflict with morphological changes of the trigeminal nerve is highly associated to classical
TN, however this finding is only present in half of the patients with classical TN.
. First line treatment is prophylactic medication with sodium channel blockers, and in medically refractory
patients surgical treatment is the next step.
. Future research should focus on uncovering risk factors in classical TN, on prospective studies using inde-
pendent assessors of surgical outcome, on exploring new drugs and on investigating the efficacy of neuro-
stimulation, botulinum toxin and combination treatment with existing drugs.
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